(-0.76%) 5 068.75 points
(-0.25%) 38 582 points
(-1.40%) 17 417 points
(0.05%) $82.85
(-1.81%) $1.623
(-0.26%) $2 332.30
(-0.30%) $27.27
(-0.20%) $914.00
(-0.19%) $0.933
(-0.13%) $10.97
(-0.22%) $0.801
(-0.07%) $92.26
5 days till quarter result
(bmo 2024-04-30)
Expected move: +/- 7.46%
@ $51.59
Issued: 24 Apr 2024 @ 14:15
Return: 0.29%
Previous signal: Apr 24 - 11:58
Previous signal:
Return: 0.16 %
Live Chart Being Loaded With Signals
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally...
Stats | |
---|---|
Today's Volume | 1.55M |
Average Volume | 1.75M |
Market Cap | 11.62B |
EPS | $0 ( 2024-02-13 ) |
Next earnings date | ( $0.870 ) 2024-04-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.52 |
ATR14 | $0.695 (1.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Clancy Paul J | Buy | 403 | Common Stock |
2024-03-28 | Harrigan Edmund | Buy | 413 | Common Stock |
2024-03-28 | Baker Bros. Advisors Lp | Buy | 543 | Common Stock |
2024-03-28 | Baker Bros. Advisors Lp | Buy | 543 | Common Stock |
2024-03-25 | Trotta Matteo | Buy | 21 868 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
79.25 |
Last 98 transactions |
Buy: 1 089 090 | Sell: 137 626 |
Volume Correlation
Incyte Corp Correlation
10 Most Positive Correlations | |
---|---|
RNRG | 0.927 |
JFU | 0.921 |
GOEV | 0.92 |
LSXMA | 0.92 |
LSXMK | 0.92 |
TTMI | 0.918 |
ALHC | 0.914 |
ATSG | 0.912 |
SILC | 0.912 |
TTOO | 0.909 |
10 Most Negative Correlations | |
---|---|
APOP | -0.914 |
CMLF | -0.907 |
TYHT | -0.902 |
CPTA | -0.894 |
ICON | -0.893 |
EBSB | -0.892 |
GALT | -0.891 |
XPON | -0.886 |
SCR | -0.886 |
XLRN | -0.884 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Incyte Corp Correlation - Currency/Commodity
Incyte Corp Financials
Annual | 2023 |
Revenue: | $3.70B |
Gross Profit: | $3.44B (93.10 %) |
EPS: | $2.67 |
Q4 | 2023 |
Revenue: | $1.01B |
Gross Profit: | $943.54M (93.11 %) |
EPS: | $0.900 |
Q3 | 2023 |
Revenue: | $919.03M |
Gross Profit: | $858.93M (93.46 %) |
EPS: | $0.760 |
Q2 | 2023 |
Revenue: | $954.61M |
Gross Profit: | $886.31M (92.85 %) |
EPS: | $0.910 |
Financial Reports:
No articles found.
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators